Aurobindo Pharma (BOM:524804) Moat Score: 0/10 (As of Jul. 25, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:524804 Aurobindo Pharma Ltd BOM:524804
85 GF Score
Price ₹1,531.50
GF Value ₹1,345.80
Valuation Modestly Overvalued
! 7 Warning Signs
View Full Analysis

What is Aurobindo Pharma Moat Score?

Aurobindo Pharma has the Moat Score of 0, which implies that the company might have No Moat - No discernible moat.

Aurobindo Pharma has

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Aurobindo Pharma might have No Moat - No discernible moat.

Aurobindo Pharma  (BOM:524804) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Aurobindo Pharma Moat Score Related Terms

BOM:524804
85GF Score
Aurobindo Pharma Ltd BOM:524804
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Aurobindo Pharma (BOM:524804) Overvalued in 2026?

Based on GuruFocus' analysis, Aurobindo Pharma stock appears to be overvalued. The current stock price of ₹1,531.50 is trading 13.8% above its estimated GF Value™ of ₹1,345.80. GuruFocus considers Aurobindo Pharma to be Modestly Overvalued.

Key valuation signals for BOM:524804:

  • Moat Score: 0
  • GF Value™: ₹1,345.80 vs. price of ₹1,531.50 (13.8% above fair value)
  • GF Score™: 85/100 with 7 warning signs

No single metric tells the full story. See the BOM:524804 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Aurobindo Pharma Business Description

Other Exchanges AUROPHARMA:India
Address Plot No. 1, Survey No. 83/1, Galaxy, Floors 22-24, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad, TG, IND, 500032
Aurobindo Pharma Ltd is a specialty and generic drug manufacturing company. It is principally engaged in the manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals, and related services. Its formulations target key therapeutic areas, including Central Nervous System (CNS), Antibiotics, Anti-diabetics, Cardiovascular, Anti-retroviral, Gastroenterology, Oncology, and Dermatology. The operating and reportable segments of the company are; India, the United States of America, Europe, and the Rest of the World. The company generates a majority of its revenue from its business in the United States of America.
85GF Score

Get the complete analysis for BOM:524804

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹1,531.50
Price
₹1,345.80
GF Value